

CXCR4 receptor antagonists - Pipeline Insight, 2022

<https://marketpublishers.com/r/CCA91AA6D7ECEN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: CCA91AA6D7ECEN

Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "CXCR4 Receptor Antagonists - Pipeline Insight, 2022" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in CXCR4 Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

CXCR4 Receptor Antagonists Understanding

CXCR4 Receptor Antagonists: Overview

CXCR4 is a 352 amino acid rhodopsin-like GPCR, comprising an extracellular N-terminal domain, 7 transmembrane (TM) helices, 3 extra-cellular loops (ECL), 3 intra-cellular loops (ICL) and an intracellular C-terminal domain. CXCR4 can exist in the plasma membrane as a monomer, dimer, higher-order oligomer or nanoclusters.

Function - CXCR4 can control cell proliferation in addition to directing cell retention and movement, both in physiological processes, such as development and tissue regeneration, and in pathological ones, such as cancer growth. Signal transduction pathways downstream CXCR4 eventually control both cell movement and cell proliferation, which are both dependent on PI3K-Akt and mTORC signaling; the details,

however, may vary from cell to cell and in different settings.

CXCR4 Receptor Antagonists - CXCR4 antagonists can disrupt adhesive tumor–stroma interactions and mobilize leukemia cells from their protective stromal microenvironment, making them more accessible to conventional drugs. Therefore, targeting the CXCR4-CXCL12 axis is a novel, attractive therapeutic approach that is explored in ongoing clinical trials in leukemia patients. Initially, CXCR4 antagonists were developed for the treatment of HIV, where CXCR4 functions as a co-receptor for virus entry into T cells. The diverse role of the SDF-1/CXCR4 axis in the pathogenesis of HIV, cancer, and rheumatoid arthritis, has established CXCR4 as a promising therapeutic target. Considering the vast population of patients with these diseases, the development of CXCR4 antagonists is of therapeutic as well as economic importance.

CXCR4 Receptor Antagonists Emerging Drugs Chapters

This segment of the CXCR4 Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

CXCR4 Receptor Antagonists Emerging Drugs

Burixafor: TaiGen Biotechnology

Burixafor is a highly potent CXCR4 inhibitor currently under clinical development. It can be used as a stem cell mobilizer for hematopoietic stem cell transplantation and a chemosensitizer in hematological and solid tumors. It can also be used for stem cell collection in healthy individuals for personalized regenerative medicine. The drug is currently In phase 2 of clinical trials.

USL311: Proximagen

USL311 is a potent and selective small molecule antagonist of the chemokine receptor 4 (CXCR4), a G-protein coupled receptor that is activated by stromal-derived-factor-1 (SDF-1). CXCR4 is overexpressed in many tumors. USL311 was discovered by the team based at Proximagen, Upsher-Smith's wholly-owned research subsidiary in

Cambridge, U.K., and has been moved into development by Upsher-Smith's Biotech Research Institute, the division of Upsher-Smith focused on development of new chemical entities.

Further product details are provided in the report.....

CXCR4 Receptor Antagonists: Therapeutic Assessment

This segment of the report provides insights about the different CXCR4 Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on CXCR4 Receptor Antagonists

There are approx. 10+ key companies which are developing the CXCR4 Receptor Antagonists. The companies which have their CXCR4 Receptor Antagonists drug candidates in the most advanced stage, i.e. phase II include, TaiGen Biotechnology.

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

CXCR4 Receptor Antagonists pipeline report provides the therapeutic assessment of

the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

CXCR4 Receptor Antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses CXCR4 Receptor Antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CXCR4 Receptor Antagonists drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence CXCR4 Receptor Antagonists R&D. The therapies under development are focused on novel approaches for CXCR4 Receptor Antagonists.

CXCR4 Receptor Antagonists Report Insights

CXCR4 Receptor Antagonists Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

CXCR4 Receptor Antagonists Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing CXCR4 Receptor Antagonists drugs?

How many CXCR4 Receptor Antagonists drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for CXCR4 Receptor Antagonists?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the CXCR4 Receptor Antagonists therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for CXCR4 Receptor Antagonists and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

TaiGen Biotechnology

Proximagen

AdAlta

ChemoCentryx

Polyphor

BioLineRx

X4 Pharmaceuticals

GlycoMimetics

Sanofi Genzyme

Eli Lilly and Company

Bristol-Myers Squibb

Cantex Pharmaceuticals

Altiris Therapeutics

Key Products

Burixafor

USL311

AD 214

Research programme: chemokine receptor antagonists

Balixafortide

Motixafortide

X4P-003

Mavorixafor

GMI 1359

Plerixafor

LY 2510924

Ulocuplumab

Dociparstat sodium

Q 122

Contents

Introduction

Executive Summary

CXCR4 Receptor Antagonists: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

CXCR4 Receptor Antagonists – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

CXCR4 Receptor Antagonists companies' collaborations, Licensing, Acquisition -Deal

Value Trends

CXCR4 Receptor Antagonists Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Motixafortide: BioLineRx

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Burixafor: TaiGen Biotechnology

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I/II)

Comparative Analysis

USL311: Proximagen

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

X4P-003: X4 Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

CXCR4 Receptor Antagonists Key Companies

CXCR4 Receptor Antagonists Key Products

CXCR4 Receptor Antagonists- Unmet Needs

CXCR4 Receptor Antagonists- Market Drivers and Barriers

CXCR4 Receptor Antagonists- Future Perspectives and Conclusion

CXCR4 Receptor Antagonists Analyst Views

CXCR4 Receptor Antagonists Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for CXCR4 Receptor Antagonists

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for CXCR4 Receptor Antagonists
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: CXCR4 receptor antagonists - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/CCA91AA6D7ECEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CCA91AA6D7ECEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970